Ascendis Pharma A/S Announces Three Investor Presentations in September
Details
Event | 2019 Wells Fargo Healthcare Conference |
Location | Boston |
Date | Wednesday, September 4, 2019 |
Time | 2:25 p.m. Eastern Time |
Event | Morgan Stanley 17th Annual Global Healthcare Conference |
Location | New York |
Date | Tuesday, September 10, 2019 |
Time | 2:55 p.m. Eastern Time |
Event | Bank of America Merrill Lynch Global Healthcare Conference 2019 |
Location | London |
Date | Thursday, September 19, 2019 |
Time | 10:40 a.m. British Summer Time |
A live webcast of the
About
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technologies to create new and potentially best-in-class therapies.
Ascendis is headquartered in
For more information, please visit www.ascendispharma.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply our platform technology to build a leading, fully integrated biopharma company, (ii) our expectations regarding our ability to create new and potentially best-in-class therapies and (iii) our product pipeline. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (
Ascendis,
Internal contact: | Media contact: | Investor contact: | |||
Scott T. Smith | Ami Knoefler | Patti Bank | |||
Chief Financial Officer | Head of Global Communications | Westwicke Partners | |||
(650) 352-8389 | (650) 739-9952 | (415) 513-1284 | |||
ir@ascendispharma.com | ack@ascendispharma.com | patti.bank@westwicke.com |
Source: Ascendis Pharma A/S